Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24299734 | 0.92 | KMT2A (0.38) | TLR2KMT2AMDM2BMP1MDM4 | |
| SCHEMBL21901416 | 0.85 | KMT2A (0.47) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL29508220 | 0.79 | KMT2A (0.36) | TLR2KMT2AMDM2BMP1MDM4 | |
| SCHEMBL8843737 | 0.78 | KMT2A (0.52) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL13485373 | 0.77 | KMT2A (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL13169256 | 0.77 | KMT2A (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL7801461 | 0.77 | KMT2A (0.52) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL26231259 | 0.77 | KMT2A (0.43) | TLR2KMT2AMDM2BMP1MDM4 | |
| SCHEMBL8586600 | 0.76 | KMT2A (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL889833 | 0.75 | KMT2A (0.46) | TLR2KMT2AMDM2BMP1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | TLR2 1271/4885KMT2A 3624/4885MDM2 2350/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | TLR2 1271/4885KMT2A 3624/4885MDM2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.